Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series
复制标题
DOI：
10.1515/cclm-2021-0339
复制
发表时间：
2021-08-01
影响因子：
6.8
通讯作者：
Lippi, Giuseppe
中科院分区：
文献类型：
--
作者：
Danese, Elisa;Montagnana, Martina;Lippi, Giuseppe
目的：由于普遍接种疫苗是预防2019冠状病毒病（COVID-19）的支柱，因此监测抗SARS-CoV-2中和抗体对于破译疫苗接种后的免疫反应至关重要。方法：三名医护人员接种了30 μ g BNT 162 b2 mRNA辉瑞疫苗，随后在21天后接种了第二剂相同剂量的疫苗。在基线和连续间隔，直到63天后，抽取静脉血，用于评估总免疫球蛋白（IG）抗RBD（受体结合域），抗S1/S2和抗RBD IgG，抗RBD和抗N/S1 IgM，和抗S1伊加。总IG抗RBD、抗S1/S2和抗RBD IgG水平增加91至368倍，直至首次接种疫苗后21天，然后达到平台期。第二次接种后，水平进一步升高（分别为30倍、8倍和8倍），在第35天达到峰值，但随后略有下降，并在第一次接种后50天稳定下来。抗S1伊加水平在第一次给药后7 - 11天增加，在第二次给药前略有下降，之后水平从基线增加了24倍。抗-RBD和抗-N/S1 IgM动力学与抗-S1伊加相似，尽管显示出显著较弱的增加和适度的峰，仅比基线高4至7倍。在总IG抗RBD、抗S1/S2和抗RBD IgG之间注意到高度显著的相互关联（所有r=0.99），而其它抗SARS-CoV-2抗体显示较低的相关性，尽管仍然显著。结论：BNT 162 b2 mRNA疫苗接种产生了强有力的体液免疫应答，尤其是抗SARS-Cov-2 IgG和伊加，并被第二次疫苗剂量放大。
Objectives: Since universal vaccination is a pillar against coronavirus disease 2019 (COVID-19), monitoring anti-SARS-CoV-2 neutralizing antibodies is essential for deciphering post-vaccination immune response.Methods: Three healthcare workers received 30 mu g BNT162b2 mRNA Covid-19 Pfizer Vaccine, followed by a second identical dose, 21 days afterwards. Venous blood was drawn at baseline and at serial intervals, up to 63 days afterwards, for assessing total immunoglobulins (Ig) anti-RBD (receptor binding domain), anti-S1/S2 and anti-RBD IgG, anti-RBD and anti-N/S1 IgM, and anti-S1 IgA.Results: All subjects were SARS-CoV-2 seronegative at baseline. Total Ig anti-RBD, anti-S1/S2 and anti-RBD IgG levels increased between 91 and 368 folds until 21 days after the first vaccine dose, then reached a plateau. The levels raised further after the second dose (by similar to 30-, similar to 8- and similar to 8-fold, respectively), peaking at day 35, but then slightly declining and stabilizing 50 days after the first vaccine dose. Anti-S1 IgA levels increased between 7 and 11 days after the first dose, slightly declined before the second dose, after which levels augmented by similar to 24-fold from baseline. The anti-RBD and anti-N/S1 IgM kinetics were similar to that of anti-S1 IgA, though displaying substantially weaker increases and modest peaks, only 4 to 7-fold higher than baseline. Highly significant inter-correlation was noted between total Ig anti-RBD, anti-S1/S2 and anti-RBD IgG (all r=0.99), whilst other anti-SARS-CoV-2 antibodies displayed lower, though still significant, correlations. Serum spike protein concentration was undetectable at all-time points.Conclusions: BNT162b2 mRNA vaccination generates a robust humoral immune response, especially involving anti-SARS-Cov-2 IgG and IgA, magnified by the second vaccine dose.